593 related articles for article (PubMed ID: 26659347)
1. Pilot Comparison of ⁶⁸Ga-RM2 PET and ⁶⁸Ga-PSMA-11 PET in Patients with Biochemically Recurrent Prostate Cancer.
Minamimoto R; Hancock S; Schneider B; Chin FT; Jamali M; Loening A; Vasanawala S; Gambhir SS; Iagaru A
J Nucl Med; 2016 Apr; 57(4):557-62. PubMed ID: 26659347
[TBL] [Abstract][Full Text] [Related]
2. Prospective Comparison of
Duan H; Song H; Davidzon GA; Moradi F; Liang T; Loening A; Vasanawala S; Iagaru A
J Nucl Med; 2024 Jun; 65(6):897-903. PubMed ID: 38664016
[TBL] [Abstract][Full Text] [Related]
3. Value of 68Ga-PSMA HBED-CC PET for the Assessment of Lymph Node Metastases in Prostate Cancer Patients with Biochemical Recurrence: Comparison with Histopathology After Salvage Lymphadenectomy.
Rauscher I; Maurer T; Beer AJ; Graner FP; Haller B; Weirich G; Doherty A; Gschwend JE; Schwaiger M; Eiber M
J Nucl Med; 2016 Nov; 57(11):1713-1719. PubMed ID: 27261524
[TBL] [Abstract][Full Text] [Related]
4. Prospective Evaluation of
Minamimoto R; Sonni I; Hancock S; Vasanawala S; Loening A; Gambhir SS; Iagaru A
J Nucl Med; 2018 May; 59(5):803-808. PubMed ID: 29084827
[No Abstract] [Full Text] [Related]
5. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
6. Whole-Body Integrated [
Guberina N; Hetkamp P; Ruebben H; Fendler W; Grueneisen J; Suntharalingam S; Kirchner J; Puellen L; Harke N; Radtke JP; Umutlu L; Hadaschik BA; Herrmann K; Forsting M; Wetter A
Mol Imaging Biol; 2020 Jun; 22(3):788-796. PubMed ID: 31482413
[TBL] [Abstract][Full Text] [Related]
7. Comparison of
Schollhammer R; Robert G; Asselineau J; Yacoub M; Vimont D; Balamoutoff N; Bladou F; Bénard A; Hindié E; Gallerande HC; Morgat C
J Nucl Med; 2023 Mar; 64(3):379-385. PubMed ID: 36215569
[TBL] [Abstract][Full Text] [Related]
8. The Theranostic PSMA Ligand PSMA-617 in the Diagnosis of Prostate Cancer by PET/CT: Biodistribution in Humans, Radiation Dosimetry, and First Evaluation of Tumor Lesions.
Afshar-Oromieh A; Hetzheim H; Kratochwil C; Benesova M; Eder M; Neels OC; Eisenhut M; Kübler W; Holland-Letz T; Giesel FL; Mier W; Kopka K; Haberkorn U
J Nucl Med; 2015 Nov; 56(11):1697-705. PubMed ID: 26294298
[TBL] [Abstract][Full Text] [Related]
9. Integrated
Lütje S; Cohnen J; Gomez B; Grüneisen J; Sawicki L; Rübben H; Bockisch A; Umutlu L; Pöppel TD; Wetter A
Nuklearmedizin; 2017 Jun; 56(3):73-81. PubMed ID: 28401244
[TBL] [Abstract][Full Text] [Related]
10.
Vinsensia M; Chyoke PL; Hadaschik B; Holland-Letz T; Moltz J; Kopka K; Rauscher I; Mier W; Schwaiger M; Haberkorn U; Mauer T; Kratochwil C; Eiber M; Giesel FL
J Nucl Med; 2017 Dec; 58(12):1949-1955. PubMed ID: 28637799
[No Abstract] [Full Text] [Related]
11. Detection Efficacy of Hybrid
Einspieler I; Rauscher I; Düwel C; Krönke M; Rischpler C; Habl G; Dewes S; Ott A; Wester HJ; Schwaiger M; Maurer T; Eiber M
J Nucl Med; 2017 Jul; 58(7):1081-1087. PubMed ID: 28209912
[TBL] [Abstract][Full Text] [Related]
12. Comparison of [(18)F]DCFPyL and [ (68)Ga]Ga-PSMA-HBED-CC for PSMA-PET Imaging in Patients with Relapsed Prostate Cancer.
Dietlein M; Kobe C; Kuhnert G; Stockter S; Fischer T; Schomäcker K; Schmidt M; Dietlein F; Zlatopolskiy BD; Krapf P; Richarz R; Neubauer S; Drzezga A; Neumaier B
Mol Imaging Biol; 2015 Aug; 17(4):575-84. PubMed ID: 26013479
[TBL] [Abstract][Full Text] [Related]
13. PSMA PET/CT with Glu-urea-Lys-(Ahx)-[⁶⁸Ga(HBED-CC)] versus 3D CT volumetric lymph node assessment in recurrent prostate cancer.
Giesel FL; Fiedler H; Stefanova M; Sterzing F; Rius M; Kopka K; Moltz JH; Afshar-Oromieh A; Choyke PL; Haberkorn U; Kratochwil C
Eur J Nucl Med Mol Imaging; 2015 Nov; 42(12):1794-800. PubMed ID: 26162799
[TBL] [Abstract][Full Text] [Related]
14. 68Ga-RM2 PET in PSMA- positive and -negative prostate cancer patients.
Hoberück S; Michler E; Wunderlich G; Löck S; Hölscher T; Froehner M; Braune A; Ivan P; Seppelt D; Zöphel K; Kotzerke J
Nuklearmedizin; 2019 Sep; 58(5):352-362. PubMed ID: 31443113
[TBL] [Abstract][Full Text] [Related]
15.
Uprimny C; Kroiss AS; Decristoforo C; Fritz J; von Guggenberg E; Kendler D; Scarpa L; di Santo G; Roig LG; Maffey-Steffan J; Horninger W; Virgolini IJ
Eur J Nucl Med Mol Imaging; 2017 Jun; 44(6):941-949. PubMed ID: 28138747
[TBL] [Abstract][Full Text] [Related]
16. PSA levels, PSA doubling time, Gleason score and prior therapy cannot predict measured uptake of [68Ga]PSMA-HBED-CC lesion uptake in recurrent/metastatic prostate cancer.
Verburg FA; Pfister D; Drude NI; Mottaghy FM; Behrendt FF
Nuklearmedizin; 2017; 56(6):225-232. PubMed ID: 29044297
[TBL] [Abstract][Full Text] [Related]
17. Preclinical comparison of Al18F- and 68Ga-labeled gastrin-releasing peptide receptor antagonists for PET imaging of prostate cancer.
Chatalic KL; Franssen GM; van Weerden WM; McBride WJ; Laverman P; de Blois E; Hajjaj B; Brunel L; Goldenberg DM; Fehrentz JA; Martinez J; Boerman OC; de Jong M
J Nucl Med; 2014 Dec; 55(12):2050-6. PubMed ID: 25413139
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic Accuracy of Multiparametric MRI versus
Muehlematter UJ; Burger IA; Becker AS; Schawkat K; Hötker AM; Reiner CS; Müller J; Rupp NJ; Rüschoff JH; Eberli D; Donati OF
Radiology; 2019 Nov; 293(2):350-358. PubMed ID: 31502937
[TBL] [Abstract][Full Text] [Related]
19. Biodistribution of [(68)Ga]PSMA-HBED-CC in Patients with Prostate Cancer: Characterization of Uptake in Normal Organs and Tumour Lesions.
Prasad V; Steffen IG; Diederichs G; Makowski MR; Wust P; Brenner W
Mol Imaging Biol; 2016 Jun; 18(3):428-36. PubMed ID: 27038316
[TBL] [Abstract][Full Text] [Related]
20. PSA-Stratified Performance of
Dietlein F; Kobe C; Neubauer S; Schmidt M; Stockter S; Fischer T; Schomäcker K; Heidenreich A; Zlatopolskiy BD; Neumaier B; Drzezga A; Dietlein M
J Nucl Med; 2017 Jun; 58(6):947-952. PubMed ID: 27908968
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
